Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT

Study Overview
=================
Brief Summary
-----------------
In the study, we aimed to characterize the role of FDG PET/CT surveillance at 12 months of malignant lymphoma in asymptomatic patients after a first complete remission and to define a rational follow-up strategy.

Detailed Description
-----------------
Most aggressive lymphomas are sensitive to first-line immunochemotherapy and are in first Complete Remission (CR) with initial therapy. CR significantly decreases the risk of recurrence and increases survival. However, a cure is not guaranteed and approximately one third of lymphoma patients have a relapse disease. FDG PET/CT is a valuable noninvasive tool in the evaluation of lymphomas, especially to differentiate viable lymphoma and fibrosis or necrosis in residual mass. The majority of relapses are diagnosed based on clinical symptoms reported by patients. And the role of FDG PET/CT for routine surveillance of patients after treatment is controversial. However, many medical centers use routine follow-up FDG PET/CT in addition to physical examination and laboratory analysis to detect subclinical relapse. Thus, we can imagine a good timing to routine FDG PET/CT when the tumor burden is small in the asymptomatic window. Survival improvement for relapse detected by routine follow-up imaging is not clearly established compared to diagnosis by clinical symptoms. Several studies tried to assess the value of follow-up FDG PET/CT but population, type, timing and duration of surveillance imaging was very heterogeneous.

Official Title
-----------------
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT of Patients in Complete Remission of Malignant Lymphoma

Conditions
-----------------
Malignant Lymphoma, Relapsed Non Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Diagnostic Imaging

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first diagnosis of aggressive lymphoma, complete metabolic remission after a first-line of chemotherapy, no relapse in the first year after the end of treatment Exclusion Criteria: minor patient, pregnant woman, legal protection (legal curatorship / guardianship), absence of consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| role of FDG-PET/CT surveillance at 12months of lymphoma in asymptomatic patient in first complete remission | detection rate of relapse at 1 year and at the end of follow-up | one day | 
| performances FDG-PET/CT 1 year | sensitivity, sensibility, predictive negative value, predictive positive value, accuracy | one day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival and progression-free survival | as the time from the end of first-line chemotherapy | one day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aggressive non-hodgkin lymphoma, hodgkin lymphoma, FDG-PET/CT, follow-up, routine surveillance